EHA 2026: Advances in Sickle Cell Disease and Beta-Thalassemia

Recent developments in sickle cell disease, beta-thalassemia, and hemoglobinopathy screening are highlighted by Andreas Glenthøj, MD, PhD, Associate Professor and Head of the Danish Red Blood Cell Center at Rigshospitalet, Copenhagen, Denmark, at the EHA 2026 Congress. He discusses promising data from the RISE UP study of mitapivat in sickle cell disease, emerging treatment options for beta-thalassemia, and the increasing availability of gene therapy. He also reviews new EHA guidelines on antenatal hemoglobinopathy screening.